Pharma company's RMB30 million patent windfall emphasises need for greater Chinese IP value expertise

China’s desperate need for more IP strategy expertise is an issue that this blog has addressed on several occasions previously. A story IAM heard from a senior IP executive at a Chinese pharmaceutical manufacturer last week drives the point home.

Get unlimited access to all IAM content